Skip to main content
. Author manuscript; available in PMC: 2023 Jul 17.
Published in final edited form as: Mol Cancer Ther. 2021 Jun 4;20(8):1400–1411. doi: 10.1158/1535-7163.MCT-20-0710

Figure 4. Chemotherapy and venetoclax combine to control neuroblastoma tumor growth.

Figure 4.

(A) Plot of maximum bliss synergy scores up to 1μM from 72h cell viability assays using the combination of chemotherapy (cyclo/topo), and venetoclax. (B) Western blot of MYCN-amplified cell lines treated for 48h with 1μM of venetoclax, 1μM of cyclophosphamide and 10nM of topotecan, or a combination of both conditions. Antibodies used to detect proteins are indicated. (C and D) MYCN-amplified cell lines were transduced with scramble control or shNOXA virus and (C) viability assays were performed with the indicated drugs for 72h, or (D), Western blotted following 48h of treatment with 1μM of venetoclax, 1μM of cyclo and 10nM of topotecan and probed with the indicated antibodies. (E) The indicated PDX models or the NB-1643CRX (crizotinib resistant) xenograft model were treated with chemotherapy, venetoclax, or a combination of both treatments for the indicated timeframes (dose stoppage is indicated by an arrow). Tumor size is presented as cm3.